美国成人重度斑秃治疗Delphi共识声明
共识推荐口服Janus激酶抑制剂作为所有重度斑秃成人患者的主要长期治疗,合并特应性疾病的患者可选用度普利尤单抗作为替代方案。
要点
- 口服JAK抑制剂为重度斑秃成人主要长期治疗
- 合并特应性体质者可选用度普利尤单抗替代
- 米诺地尔、糖皮质激素等可作为补充治疗
核心结论
- 专家共识确立美国成人重度斑秃的治疗方案,口服JAK抑制剂为主要长期治疗。
研究设计与样本
- 纳入标准为成人(≥18岁)、中度至重度斑秃(SALT评分>20%)且以英文发表的研究。
主要发现
- 口服JAK抑制剂为所有患者的主要长期治疗,度普利尤单抗为合并特应性者的替代选择。
- 补充治疗包括口服及外用米诺地尔、病灶内/口服/高效价外用糖皮质激素、外用JAK抑制剂及前列腺素类,按部位有特定适应证。
关键数值与推荐
- 重度斑秃定义采用Alopecia Areata Scale;共识阈值≥70%同意。
临床怎么用
- 对重度斑秃成人以口服JAK抑制剂为长期治疗主线,合并特应性者考虑度普利尤单抗。
- 按体表部位选择米诺地尔、糖皮质激素、外用JAK抑制剂或前列腺素类作为补充。
- 医疗治疗同时应提供患者支持资源。
局限性
- 推荐不适用于儿童、孕妇、轻中度患者或合并基础疾病者。
- 需高质量研究验证现有疗法在亚人群中的疗效并开展头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alopecia areata (AA) is an autoimmune hair loss disorder that affects more than 7 million people in the US. Before US Food and Drug Administration-approved trials of Janus kinase inhibitors, numerous treatments had been explored, with variable efficacy and quality of evidence. The absence of standardized treatment guidelines may lead to poor treatment outcomes and payer coverage. OBJECTIVE: To establish a consensus on treatment for adults with severe AA in the US. EVIDENCE REVIEW: Systematic literature reviews for all known therapies used for treating AA were performed in PubMed from inception to December 2024. Inclusion criteria required studies to be randomized clinical trials or have an observational design, evaluate adult (≥18 years old) participants with moderate to severe AA (defined by Severity of Alopecia Tool scores >20%), and be published in English. Studies were excluded if they included patients with non-AA hair loss or if they exclusively evaluated pediatric participants or those with mild AA (Severity of Alopecia Tool scores ≤20%). Three rounds of anonymous, iterative online surveys were administered from May through November 2025. Consensus was predefined at an agreement threshold of 70% or greater. A definition of AA severity was proposed for determining patient eligibility. Experts with recent AA-related research and extensive clinical experience treating adults with severe disease indicated their agreement or disagreement with the use of 29 treatments for adults with severe AA. Treatments that reached consensus for inclusion were further explored with respect to therapeutic positioning, treatment regimens, and long-term management. FINDINGS: Thirty-one US-based AA experts completed 3 rounds of iterative surveys. Consensus was achieved on treatment of adults with severe alopecia areata, as defined by the Alopecia Areata Scale. Oral Janus kinase inhibitors represented the primary, long-term therapy for all patients, with dupilumab as an alternative option for patients with comorbid atopy. Supplemental treatments included oral and topical minoxidil; intralesional, oral, and high-potency topical corticosteroids; and topical Janus kinase inhibitors and prostaglandins, with body site-specific indications. Patient support resources should be offered alongside medical treatment. CONCLUSION AND RELEVANCE: This study defines expert-established consensus on treatment of adults with severe AA in the US. Additional high-quality investigations are needed to establish the efficacy of existing therapies in subpopulations and enable head-to-head comparisons of new and existing interventions. These recommendations are not indicated for children, pregnant patients, patients with mild to moderate disease, or those with underlying comorbidities; additional research is needed to inform treatment guidelines for these specific patient populations.
引用
- Gregoire S, Dewey E, Biba U, et al. Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults. JAMA Dermatol. 2026. PMID: 42684692. doi:10.1001/jamadermatol.2026.2336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。